Emergent BioSolutions Gets FDA Greenlight for Multipacks of Narcan
By Elias Schisgall
Emergent BioSolutions received Food and Drug Administration approval for its multipack configuration of Narcan, the opioid-overdose-reversal drug.
The company said Friday that the FDA greenlit over-the-counter sales of Narcan in packs of six and 24. It said the multipack offerings would meet the needs of community programs and organizations that distribute Narcan at a large scale.
"The introduction of Narcan Nasal Spray multipacks marks a significant step in empowering our partners on the front line," Paul Williams, Emergent's head of products business and global government and public affairs, said.
"They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency," he added.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
February 12, 2026 18:51 ET (23:51 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States